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Abstract
INTRODUCTION: PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) recep-
tors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor
receptor. Cetuximab is a monoclonal antibody against epidermal growth factor (EGF) receptor. Combining inhibi-
tion of VEGF and EGF signaling might act additive or synergistically. METHODS: In phase 1 design, patients with
advanced solid tumors were treated with PTK/ZK daily (cohort 1, 750 mg once daily; cohort 2, 1250 mg once daily;
cohort 3, 250 mg [morning] and 500 mg [evening]; and cohort 4, 500 mg [morning] and 750 mg [evening]) in com-
bination with cetuximab 250 mg/m2 weekly in cycles of 28 days in cohorts of three patients. Toxicity was evaluated
conform the Common Terminology Criteria for Adverse Events classification 3.0. Pharmacokinetics and pharmaco-
dynamics consisting of circulating endothelial (progenitor) cell (CE[P]C) analysis by flow cytometry were per-
formed. RESULTS: Safety and tolerability was evaluated in 16 patients. The most frequently reported adverse
events were acne, dry skin, fatigue, nausea, dizziness, vomiting, headache, and diarrhea. One dose-limiting toxicity
occurred in cohort 3 consisting of a grade 3 transaminitis. Pharmacokinetic analysis revealed no significant changes
in PTK/ZK exposure on coadministration with cetuximab and in bioavailability at equivalent total daily doses. Bio-
marker analysis showed no significant change in the number of CE(P)Cs during treatment. One of 14 evaluable pa-
tients showed a partial response for at least 11.5 months, and 7 patients (50%) stable disease for at least 2 months.
CONCLUSIONS: This study shows that the combination of PTK/ZK and cetuximab is well tolerated with only slightly
overlapping toxicity profiles and has antitumor activity.
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Introduction
Therapies directed against vascular endothelial growth factor (recep-
tor) (VEGF[R]) and epidermal growth factor receptor (EGFR) have
shown their clinical benefit in the treatment of cancer [1–8]. VEGF
is a multifunctional cytokine that increases microvascular permeabil-
ity and directly stimulates endothelial cell growth and angiogenesis
[9]. The angiogenic signal is transmitted through cell surface recep-
tors (VEGFR-1 and VEGFR-2) located on the tumor vascular endo-
thelium. These receptors have intracellular tyrosine kinase activity.
Binding of VEGF to VEGFR-2 results in the induction of several
proteins, including tissue factor, urokinase, tissue-type plasminogen
activator, plasminogen activation inhibitor 1, matrix metallopro-
teinase, and antiapoptotic factors facilitating and supporting tumor
growth and tumor metastasis formation [10]. The HER1 receptor
or EGFR is a prominent member of the HER growth factor receptor
family. Signaling through this receptor activates a cascade that leads
to proliferation, migration, survival signals, and tissue remodeling.
The EGFR is overexpressed in a variety of cancers. Overexpression
may range from 10% to 80% in cancer. Its expression has been as-
sociated with poor survival [11].
On the basis of the current knowledge of tumor biology, there is a
rationale to combine targeted therapies that block different growth
factor pathways. Although generally targeted separately, the EGFR
and VEGFR pathways are interconnected. The EGFR pathway is
implicated in several processes that control angiogenesis and is pres-
ent on the endothelial cells of tumor vasculature [12]. Activation of
EGFR leads to the induction of several angiogenic factors in tumor
cells, including hypoxia-inducible factor 1 stabilization through
phosphatidylinositol-3 kinase/AKT pathway activity in addition to
enhanced production of VEGF by activation of the mitogen-activated
protein kinase pathway. In vitro and in vivo studies show that the
up-regulation of these proangiogenic factors could be inhibited by
an EGFR-neutralizing antibody [13].
In addition, coexpression of EGFR and transforming growth fac-
tor α is closely associated with microvessel density in invasive cancers
[14]. Preclinical studies show that inhibition of both EGFR and
VEGF pathways produces additive or synergistic antitumor effects
[15,16]. Finally, it has recently been published that VEGFR-1 con-
tributes to anti-EGFR drug resistance in different human cancer
cells. Interestingly, impeding VEGFR-1 activation restored sensitivity
to anti-EGFR drugs [17].
Furthermore, combination treatment of enzostaurine, a protein
kinase C, β1 inhibitor, with EGFR inhibitor gefitinib, overcame re-
sistance to EGFR inhibitors in gefitinib-resistant tumor cell lines
[18]. Data from early clinical studies combining VEGF antibody
bevacizumab with erlotinib in non–small cell lung carcinoma, adeno-
carcinoma of unknown primary, breast cancer, and renal cell cancer
have been encouraging [19–23], and phase 3 trials with this combina-
tion treatment in non–small cell lung carcinoma are ongoing at this
moment. Overall, it is conceivable that in malignancies being EGFR
and VEGF signaling–dependant for growth and proliferation, inhibi-
tion of EGFR signaling, in combination with attenuation of VEGF-
induced angiogenesis, would result in an additive/complementary or
even synergistic therapeutic effect.
PTK/ZK (PTK787/ZK 222584) (vatalanib), belonging to the
chemical class of aminophthalazines, is a potent and relatively selec-
tive small-molecule tyrosine kinase inhibitor of VEGFR-1, -2, and -3,
platelet-derived growth factor receptor (c-Fms), cytokine stem cell fac-
tor receptor (c-kit), and colony-stimulating factor 1 receptor. PTK/ZK
was evaluated in two phase 3 trials (CONFIRM 1 and 2) in advanced
colorectal cancer in combinationwith chemotherapy [24,25]. Cetuximab
(Erbitux) is a chimeric immunoglobulin G subclass 1 monoclonal anti-
body that blocks the binding of EGF to its receptor, inhibits cell prolif-
eration, tumor neoangiogenesis, and metastatic potential, and promotes
tumor cell apoptosis. Clinical activity has been demonstrated when given
as a single agent in patients with previously treated colorectal cancer
and has been approved in colorectal cancers without K-RAS mutation
[4]. The combination of VEGF and EGFR inhibitors has not been ex-
tensively tested. A recently published phase 3 trial in colorectal can-
cer patients showed that the addition of cetuximab to capecitabine,
oxaliplatin, and bevacizumab resulted in an unexpected, significantly
shorter progression-free survival and inferior quality of life. Mutation sta-
tus of the KRAS gene was a predictor of outcome in the cetuximab group
[26]. Presently, there is no good explanation for this finding. It has led
investigators back to the bench and the design of early clinical studies
to elucidate the molecular mechanism behind the synergism or the
antagonism between biologically based targeted therapies [22,27].
In this phase 1 study, we studied the safety of PTK/ZK in com-
bination with cetuximab. Secondary objectives included determina-
tion of the pharmacokinetic (PK) profile of PTK/ZK in combination
with cetuximab, definition of the optimal dosing regimen (once- or
twice-daily PTK/ZK), investigation of the effect of PTK/ZK on
markers of biologic activity (circulating endothelial cell measure-
ments), and preliminary evaluation of efficacy.
Patients and Methods
Eligibility Criteria
In this single-center, phase 1 study, patients older than 18 years
with advanced solid tumors refractory to or failing standard treat-
ment were included. Patients were required to have a World Health
Organization performance status of 2 or lower and adequate bone
marrow, renal, and liver functions.
The most important exclusion criteria were a history of central
nervous system tumors or metastases, surgery less than 10 days before
the start of the study treatment or inadequate recovery from previous
therapies including surgery, radiation, chemotherapy, biologic, or im-
munotherapy, a history of cardiac disease, congestive heart failure
higher than 2 according to the New York Heart Association system,
active coronary artery disease less than 6 months to study entry, car-
diac arrhythmias requiring antiarrhythmic therapy, concurrent treat-
ment with proton pump inhibitors, poorly controlled hypertension,
uncontrolled infections, impairment of gastrointestinal function that
may significantly alter the absorption of PTK/ZK, presence of un-
controlled diabetes, and proteinuria and patients who received exper-
imental agents or radiation therapy within 4 weeks of the start of the
study. The study was approved by the institutional ethical commit-
tee, and all patients provided written informed consent (IC). The
trial was conducted in accordance with the Declaration of Helsinki.
Trial Design
In this phase 1, monocenter, open-label study conducted in a
dose-escalation study design, patients were included in four cohorts
of three patients with increasing dose of PTK/ZK and once- or twice-
daily dosing regimens. Cetuximab was administered at a fixed dosage
of 250 mg/m2 (with a loading dose of 400 mg/m2) weekly in all four
cohorts, starting from day 8. PTK/ZK was given once (morning dose,
Neoplasia Vol. 12, No. 2, 2010 Combination Treatment with PTK/ZK and Cetuximab Langenberg et al. 207
cohorts 1 and 2) or twice daily (morning and evening dose, cohorts 3
and 4) continuously in an escalating dose. A treatment cycle comprised
28 days. Predefined maximum dose of PTK/ZKwas 1250mg total daily
based on previous single-agent studies (Table 1) [28,29]. PTK/ZK was
provided by Bayer Schering Pharma (Mijdrecht, The Netherlands). In
all four cohorts, patients received PTK/ZK and cetuximab until tumor
progression or uncontrolled toxicity was observed. This study design
allowed to simultaneously start cohorts 1 and 3 and, subsequently,
cohorts 2 and 4. Toxicity was evaluated according to Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0. Dose-limiting
toxicity (DLT) was defined as a grade 3 nonhematological adverse event
(AE) related to the combination regimen or PTK/ZK alone and un-
related to the patients’ underlying disease or concomitant medications,
occurring during the first cycle of treatment with exception of nausea
and diarrhea well controlled by intervening treatment. Neutropenia
CTCAE grade 4, platelet count of 50 × 109/L or less, serum creatinine
level of 2.5 × upper limit of normal or higher, proteinuria on dip stick
reading CTCAE grade 2 or higher confirmed by a 24-hour urine collec-
tion with a protein level of 1.0 g or higher, hematuria CTCAE of grade 2
or higher, and suspicion of reversible posterior leukoencephalopathy
syndrome were also considered to be a DLT. Toxicity solely related to
the cetuximab was not considered as DLT. In case of a DLT, the cohort
was expanded to six patients. The maximum tolerated dose (MTD) was
defined as the dose level at which none or one of six patients experienced
a DLT with at least two patients experiencing DLT at the next higher
dose level. Safety review meetings were held for each cohort, before en-
tering the next cohort. Screening assessments consisted of a complete
medical history, current medication history, a complete physical exami-
nation, disease assessment, 12-lead electrocardiogram, clinical chemistry,
hematology, and urinalysis. At every biweekly visit during the course of
the study, a physical examination, assessment of AEs, clinical chemistry,
hematology, and urinalysis was performed. Tumor assessment was per-
formed before start of the study and every 2 months thereafter or at the
discretion of the investigator. Response was assessed using the Response
Evaluation Criteria in Solid Tumors guidelines [30].
PK Analysis
Blood samples for PK were collected into precooled heparinized
tubes at baseline (after light breakfast) after 20 minutes and at 1,
1.5, 2, 4, 6, 8, and 24 hours after the dose of PTK/ZK, on cycle 1
day 7 (pre–cetuximab administration), day 8 (post–cetuximab admin-
istration), and on day 15 (cetuximab steady state). Within 30 minutes,
plasma was prepared by centrifugation (2000g at 4°C for 10 minutes)
and stored at −70°C until analysis. At the time of analysis, plasma
monsters were diluted in blank human EDTA plasma. Plasma PTK/
ZK concentrations were determined by reverse-phase high-performance
liquid chromatography coupled with tandem mass spectrometry ac-
cording to a validated method. Parameters to be determined were
area under the concentration–time curve from the time of dosing
to the last measurable concentration (AUC0-24, calculated by linear
trapezoidal summation), maximum observed plasma concentration
(Cmax), time of maximum observed plasma concentration (Tmax),
and the terminal half-life (t1/2) using PK solutions 2.0 software
(Summit Research Services, Montrose, CO). AUC0-24 for the second
gift of PTK/ZK (cohorts 3 and 4) was calculated from data from the
first gift by the formula “F × Dose = Cl × AUC” with the assump-
tion that clearance (Cl) and bioavailability (F) were unchanged.
Biomarker Studies
Blood samples for the measurement of circulating endothelial (pro-
genitor) cells (CE[P]Cs) were collected on cycle 1 day 1 predose (base-
line), day 8 predose (t = 0) and t = 4 and 24 hours after cetuximab
infusion, and on day 8 predose (t = 0) and t = 4 and 24 hours after
cetuximab infusion. Mononuclear cells were isolated by means of an
8-ml cell preparation tube (Becton Dickinson, Breda, The Netherlands).
CE(P)Cs were quantified by four color flow cytometry using CD45,
CD31, CD146, and CD133 as surface markers as previously re-
ported, defining endothelial progenitor cell as CD45−, CD31+, and
CD133+, circulating mature endothelial cell as CD45−, CD31+, and
CD146+, and progenitor cell as CD133+ [31].
It was hypothesized that combination treatment with PTK/ZK
and cetuximab would stabilize CE(P)C levels. Statistical comparisons
between baseline and subsequent measurements were performed
using the Students t test. All tests were two-sided. P < .05 was consid-
ered statistically significant (GraphPad Prism 4.0 [GraphPad Software,
Inc, La Jolla, CA] and SPSS version 15 [SPSS, Inc, Chicago, IL]).
Results
Patient Population
A total of 24 patients were screened of which 18 patients were
enrolled in the study divided over four different dose-escalating co-
horts (Table 1). There were six screenings failures due to proteinuria
(n = 2), uncontrolled hypertension, persistent anemia due to blood
loss in the digestive tract, hyperbilirubinemia based on hepatic in-
volvement, and an indication for proton pump inhibitor use due
to a gastric ulcer (all n = 1). The median age of the patients was
61 years (range, 43-78 years). Additional patient characteristics are
provided in Table 2.
Determination of the Recommended Dose
Cohort 1 (750 mg of PTK/ZK once daily) enrolled three patients
(Table 1). The combination treatment at this dose level was well tol-
erated. Cohort 2 (1250 mg of PTK/ZK once daily) enrolled another
set of three patients. No DLTs were observed, but a grade 2 proteinuria
together with a grade 3 hypertension in one patient occurred. The
event occurred before day 8, and this particular patient had not re-
ceived combination treatment. Given that the proteinuria was already
preexistent at the start of the study (note to file) and the hypertension
was immediately well managed with antihypertensive treatment, these
events were both considered not DLTs. This patient was replaced.
Taken together, no DLTs were observed at this dose level.
Table 1. Study Design and Assignment of Patients.
Cohort Dose of No. Patients
PTK/ZK (Daily) Cetuximab
(Weekly)* (mg/m2)
Screened Enrolled† Treated‡ DLT
1 750 mg morning dose 250 3 3 3 —
2 1250 mg morning dose 250 5 4 3 —
3 250 mg morning dose 250 10 7 6 1
500 mg evening dose
4 500 mg evening dose 250 6 4 4 —
750 mg morning dose
*First cetuximab administration after 7 days, preceded by loading dose of 400 mg/m2.
†Patients screened who met inclusion and exclusion criteria.
‡Patients who received combination treatment for at least 7 days.
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In cohort 3 (750 mg of PTK/ZK twice daily), initially three pa-
tients were enrolled. No DLTs were observed. However, several likely
PTK/ZK–related grade 2 and three grade 3 AEs occurred (liver bio-
chemistry disturbances, hypertension, and deep venous thrombo-
embolism) just beyond the predefined safety period of 28 days.
Therefore, it was decided by the investigators to expand this cohort
to six patients. In these additional three patients, one DLT occurred
(aspartate aminotransferase [AST] increase grade 3). One patient with a
grade 4 anaphylactic reaction directly after the first cetuximab infusion
was replaced. In addition, one patient presented with grade 3 acne likely
because of noncompliance of the patient to the recommended derma-
tological supportive care. The skin toxicity quickly reversed to grade 1
with structured and intensive dermatological support. On the basis of
these findings, the investigators decided that it was safe to enroll pa-
tients at the final dose level.
Cohort 4 (1250 mg of PTK/ZK twice daily) included four pa-
tients in total. One patient with pancreatic cancer withdrew IC after
14 days of treatment because of symptoms of a preexistent mood
disorder. This patient was replaced. No DLTs occurred at this dose
level. A grade 3 increase in γ-glutamyl transpeptidase and a grade 3
hyponatremia and tachycardia (one patient) were observed. However,
because these events were unrelated to the study treatment or already
existent at the start of the study, they were not considered DLTs. The
study was terminated at this dose level because the recommended
dose for PTK/ZK from single-agent phase 1 studies was attained.
Safety and Tolerability
Of all 18 patients assigned to study treatment, 16 patients received
combination therapy and therefore were assessable for safety analysis.
Two patients went off the study before or during the first cetuximab
administration. Overall, the combination of PTK/ZK and cetuximab
was well tolerated.
Drug-related AEs (all grades) reported by more than 30% of the
patients were acne (87%), dry skin (81%), fatigue (69%), nausea
(63%), dizziness (50%), vomiting (50%), headache (38%), diarrhea
(31%), fissures of the skin (31%), and hypertrichosis (31%). Fre-
quencies of treatment-related AEs CTCAE grade 2 and 3 are pre-
sented in Table 3. Grade 3 toxicity was most frequently observed
in cohorts 3 and 4. During the whole study, only one DLT consisting
of a grade 3 increase in AST and only one CTCAE grade 4 toxicity
comprising an anaphylactic reaction after cetuximab administration
were reported. This anaphylactic reaction was well controlled with
immediate intervention (epinephrine and antihistamines) and was un-
doubtedly cetuximab-related. Serious adverse events possibly related
to study treatment consisted of pneumonia and a pneumothorax
and resolved well after admission for intravenous antibiotic treatment
and pleural drainage, respectively.
Treatment-related skin toxicity (all CTCAE grades) was observed
in 15 of the 16 evaluable patients. These AEs were mainly classified
as CTCAE grade 2/3 and were well manageable with structured and
intensive dermatological support.
Fatigue was the second most frequently reported symptom (69%,
CTCAE grade 1 n = 8; CTCAE grade 2 n = 3), interfering with daily
activities while on treatment, but not being a reason to discontinue
Table 2. Patient Characteristics.
No.
No. patients enrolled 18
Sex
Male 10
Female 8
Age (years)
Median 61
Range 43-78
WHO status
0 12
1 5
2 1
Primary tumor
Colorectal cancer 10
Cholangiocarcinoma 1
Pancreatic cancer 1
Bronchus carcinoma 1
Chordoma 2
Breast cancer 1
Ovarian cancer 1
Cervix uteri carcinoma 1
No. metastatic sites
1 3
2 3
3 4
4 4
5 2
≥6 2
Prior therapy
Surgery 15
Systematic therapy 18
Radiotherapy 6
No. previous chemotherapy regimens
1 1
2 6
3 5
≥4 2
Time from first diagnosis (years)
Median 1.8
Range 0.1-13.1
WHO indicates World Health Organization.
Table 3. Combination Treatment Emergent–Related AEs CTCAE Grade 2 and 3.
Toxicity Toxicity Grade (No. Patients)*
Grade 2 Grade 3
Cohort Total (%) Cohort Total (%)
1 2 3 4 1 2 3 4
Abscess 1 0 0 0 1 (6) 0 0 0 0 0
Acne 0 0 1 2 3 (19) 0 1 0 0 1 (6)
Cardiac ischemia 0 0 1 0 1 (6) 0 0 0 0 0
Dizziness 0 1 1 0 2 (12) 0 0 0 0 0
Dry skin 1 0 1 0 2 (12) 0 0 0 0 0
VTE 0 0 0 0 0 0 0 1 0 1 (6)
Fatigue 0 0 2 1 3 (19) 0 0 0 0 0
Headache 0 0 1 0 1 (6) 0 0 0 0 0
Hypertension 0 1 0 1 2 (12) 0 0 2 0 2 (12)
Nausea 0 0 1 1 2 (12) 0 0 0 0 0
Neutropenia† 1 0 0 0 1 (6) 0 0 1 0 1 (6)
Proteinuria† 0 1 1 0 2 (12) 0 0 0 0 0
Heartburn 0 0 1 0 1 (6) 0 0 0 0 0
Rash perianal 0 0 1 0 1 (6) 0 0 0 0 0
Transaminitis (ALT)† 1 1 1 0 3 (19) 1 0 2 0 3 (19)
Transaminitis (AST)† 2 1 2 0 4 (25) 0 0 1‡ 2 3 (19)
Vomiting 0 0 1 1 2 (12) 0 0 0 0 0
Total AE 6 5 15 6 1 1 6 2
ALT indicates alanine transaminase; VTE, venous thromboembolism.
*Sixteen patients were assessable for safety analysis.
†For laboratory/metabolic disturbances, all emerging AEs are displayed.
‡DLT for that cohort.
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study medication. Hypertension occurred in 4 (25%) of the 16 pa-
tients (CTCAE grade 2 n = 2; CTCAE grade 3 n = 2) and was well
controlled by a standardized hypertension management protocol,
commencing with a calcium channel blocker followed, when needed,
by a β-blocker or by an angiotensin-converting enzyme inhibitor.
Dizziness occurred in 8 (50%) of the 16 patients (CTCAE grade 1
n = 6; CTCAE grade 2 n = 2). The total reported related AEs (all
CTCAE grades) for the four successive cohorts were 57, 63, 121, and,
80 respectively.
The median number of days on treatment for all 16 patients in the
four cohorts was 49 (range, 34-214), 134 (range, 7-344), 48 (range,
6-331), and 46 (range, 14-57), respectively. Eleven patients discon-
tinued study permanently owing to progressive disease, four patients
owing to toxicity (liver disturbances n = 2, cetuximab-related anaphy-
laxis n = 1, pneumothorax n = 1), and one patient withdrew IC be-
cause of multiple toxicity (Table 4). Dose intensities for both the
study treatments differed slightly between the once- and twice-daily
cohorts in favor of the once-daily regimens. Reductions were equally
distributed among all cohorts, and there were no clear differences in
dose delays and interruptions between the once- and twice-daily dos-
ing regimens and between the two dosage groups (Table 4).
PK and Biomarker Studies
Seventeen patients were evaluable for PK analysis. PK profiles
composed for PTK/ZK are shown in Figure 1. PTK/ZK was rapidly
absorbed after oral administration, with the Cmax reached in approx-
imately 1 to 2 hours and mean half-life of PTK/ZK of 5 hours. No
significant changes in PTK/ZK exposure on coadministration with
cetuximab (PK profile days 7 and 8) were observed. Incidental
changes observed were of low magnitude and within the usual range
of interpatient variability. At equivalent total daily doses, no statis-
tically significant differences in systemic exposure (AUC0-24) for
once- and twice-daily dosing cohorts were observed. There was a
statistically significant difference in Cmax between cohorts 2 and 4
on day 7 (P < .0017) and day 8 (P < .04; Student’s t test). No sta-
tistically significant differences were found in PK profiles between
day 7 (PTK/ZK only), day 8 (combination PTK/ZK and cetuximab),
and day 15 (steady-state cetuximab). Measurements of (circulating)
endothelial (progenitor) cells by flow cytometry analysis showed
no significant changes in endothelial progenitor cell, circulating ma-
ture endothelial cells, and progenitor cell levels. There was no correla-
tion found between response to therapy and levels of (C)(E)(P)Cs
(Figure 2).
Disease Response
Of the 18 patients assigned to study treatment, 14 patients were
evaluable for efficacy analysis. Reasons for invalidity were early dis-
continuation before combination therapy was administered owing to
toxicity (n = 2, anaphylactic reaction and proteinuria) and premature
discontinuation during combination therapy which impeded evalua-
tion (n = 2, withdrawal of IC and grade 3 transaminitis). All patients
entered into the study had progressive disease at time of enrollment.
Clinical benefit was observed in eight of the 14 assessable patients
(57%). Stable disease for 2 months or longer was seen in 7 (50%)
of the 14 assessable patients (colorectal cancer n = 2, chordoma n =
2, cholangiocarcinoma n = 1, breast cancer n = 1, and cervix car-
cinoma n = 1) with a median time on study of 4.5 months (range,
2-12 months). Confirmed and sustained partial response (−40%)
with a duration of 11.5 months was observed in one patient with
colorectal cancer.
Discussion
In phase 1/2 PTK/ZK or cetuximab single-agent trials, treatment was
well tolerated. The MTD for PTK/ZK monotherapy was defined as
1250 mg once daily. On the basis of these results and the only margin-
ally overlapping toxicity profiles of the single agents, the combination
of cetuximab and PTK/ZK in escalating cohorts from subtherapeutic
to therapeutic dose was hypothesized to be tolerable and safe. The re-
sults from this current study indeed confirm that combining PTK/ZK
to cetuximab in therapeutical dosages is a safe and well-tolerated com-
bination treatment with possible biologic activity.
The toxicity profile of the combination treatment was mainly con-
sistent with the toxicity as reported in the previously mentioned single-
agent trials and consisted mainly of the known toxicities caused by
the agents individually with a trend to complementary frequencies
for certain AEs (acne, fatigue, nausea, and vomiting) [28,29]. The
combination of PTK/ZK and cetuximab did not seem to increase
the severity of these well-known toxicities caused by each agent in-
dividually. Hypertension occurred at a frequency one would expect
for a VEGF inhibitor of this class, and the occurrence of skin toxicity
was slightly increased to observed frequencies in previous studies with
cetuximab [32–34].
Both AEs could be well managed with strict and structured inter-
vention protocols, and they did not jeopardize the therapeutic poten-
tial of the treatment.
Table 4. Treatment Administration Summary*.
Cohort
1 2 3 4
Dose PTK/ZK (mg)
Morning 750 1250 250 500
Evening 500 750
Dose intensity (mean)†
PTK/ZK 0.94 0.88 0.77 0.81
Cetuximab 0.94 0.93 0.85 0.72
Days on treatment
Median (range) 49 (34-214) 134 (7-344) 48 (6-331) 46 (14-57)
Dose PTK/ZK
Reduction‡ 0 1 1 0
Delay§ 0 2 1 0
Temporarily interrupted¶ 0 2 1 0
Permanently interrupted 1 1 5 1
Reason delay/interruptions
Toxicity 1 4 5 1
Logistical 0 1 1 0
Hypersensitivity reaction 0 0 1# 0
Dose cetuximab
Reduction‡ 0 1 0 0
Delay§ 0 2 1 0
Temporarily interrupted¶ 0 3 1 0
Permanently interrupted 1 1 4 1
Reason delay/interruptions
Toxicity 1 4 4 1
Logistical 0 2 1 0
Hypersensitivity reaction 0 0 1# 0
*All enrolled patients included in the analysis (n = 18).
†Defined as proportion of planned dose to receive and dose received during 2 months of treatment.
‡Reduction of more than 10%.
§Delay of more than 3 days.
¶Temporarily interruptions defined as a delay of more than 3 days.
#Anaphylaxis to cetuximab.
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Only one DLT occurred in this study, in cohort 3, consisting of
an AST increase. Also, the fact that four patients were on treatment
for more than 7 months further endorses the fair tolerability of the
combination. On the basis of the comparison between the once- and
twice-daily cohorts for the parameters total reported AEs, the median
days on treatment, and the dose intensities, once-daily dosing regi-
mens seemed to be slightly better tolerated than twice-daily regi-
mens. Consistent with previously published studies, PK analysis
Figure 2. Measurement of (circulating) (endothelial) (progenitor) cells (C)(E)(P)Cs at various predefined time points by flow cytometry
analysis. T0 indicates baseline before PTK/ZK and cetuximab administration; T4/24, 4/24 hours after PTK/ZK administration.
Figure 1. PK analysis for PTK/ZK per cohort: once- (A and B) and twice-daily dosing cohorts (C and D). AUC indicates area under the
curve (mg h/L); Cmax, maximum observed plasma concentration (mg/L); t1/2, half-life (hours); Day 7 (after 7 days of PTK/ZK exposure),
Day 8 (PTK/ZK and cetuximab), Day 15 (steady state of combination).
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revealed no significant changes in PTK/ZK bioavailability at equiva-
lent total daily doses [28]. As a result, once-daily dosing might be
preferable than twice-daily dosing.
The study was terminated after dose level 4 because the recom-
mended doses for PTK/ZK and cetuximab from single-agent phase 1
studies were attained. No MTD was defined.
As a result, together with the comparisons between once- and
twice-daily dosing levels, the optimal treatment regimen for the com-
bination was defined as the dose level with the predefined maximum
combination dosages: PTK/ZK 1250 mg and cetuximab 250 mg/m2.
Consequently, it seems to be appropriate to conclude that once-daily
dosing might be preferable to twice-daily dosing.
Analysis of endothelial (progenitor cells) (E(P)C) levels showed
stabilized levels during the course, possibly suggesting that adminis-
tration of PTK/ZK might blunt the expected higher baseline levels
in patients with progressive disease [35,36].
The absence of additional time points with PTK/ZK only and the
heterogeneous composition of our small patient population prohibit
a definitive conclusion on this part and the findings should be con-
sidered as exploratory.
There was no correlation between disease status or response to
therapy and levels of (C)(E)(P)Cs. This was largely due to great var-
iability, possibly related to the heterogeneity and the extensive pre-
treatment of the study population.
In conclusion, this study reveals that dual targeting of the VEGFR
and EGFR pathway by means of combining PTK/ZK and cetuximab
was well tolerated at relevant single-agent doses of both agents, and
antitumor activity was found in severely pretreated patients. These
results represent a first proof of concept of combining safely an
EGF-inhibiting antibody and a VEGFR tyrosine kinase inhibitor and
support further preclinical and early clinical research concerning the
combination of EGFR and VEGF-inhibiting treatment inmalignancies
although supported by well-designed hypertension management and
dermatological care strategies.
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